Assessment of tolerance and acceptability between mannitol solution and polyethylene glycol as bowel preparation for colonoscopy: a three-center study

Evaluación de tolerancia y aceptabilidad entre la solución de manitol y el polietilenglicol como preparación intestinal para la colonoscopía: un estudio de tres centros

Jean Félix Piñerúa-Gonsálvez1,2, Rosanna del Carmen Zambrano-Infantino1,2, Alberto Baptista2, Mariseli Sulbaran3, Noheltriz Camaray1,4

1 Unit of Gastroenterology and Hepatology, Centro Clínico Andrés Bello. Ciudad Bolívar, Venezuela.
2 Department of Endoscopy, Hospital de Clínicas Caracas. Caracas, Venezuela.
3 Department of Gastroenterology, Hospital Militar “Dr. Carlos Arvelo”. Caracas, Venezuela.
4 Department of Internal Medicine, Hospital “Dr. Hector Nouel Joubert”. Ciudad Bolívar, Venezuela.

INTRODUCTION
Colonoscopy is the procedure of choice for diagnosis and therapeutic of the colonic disorders. This method has become the standard criterion for screening of colorectal cancer (CCR) because of its high accuracy for the diagnosis of early-staged cancer and its precancerous lesions (conventional adenomas and serrated colorectal lesions) (3).

Despite the recent progress in the field of colonoscopy (high-definition endoscopes, virtual chromoendoscopy, wide-angle colonoscopies, retrograde viewing devices and devices to attach to colonoscope) (3), adequate...
bowel preparation is still one of the most important factors related to the yield of colonoscopy (3). Low-quality bowel preparation has been associated with lower adenoma detection rate and cecal intubation rate; and greater need for earlier repeat colonoscopy than recommended intervals (4,5). Moreover, improper cleaning significantly increases hospital stays and healthcare expenses (6,7). Bowel preparation is perceived as an unpleasant experience by most patients, which represents a major barrier to undergo colonoscopy (8). Thus, better tolerance profiles of laxative agents are necessary to increase the adherence of patients to this procedure.

Currently, there are different available cleansing formulations used for bowel preparation. Nevertheless, none of them meet all the criteria of an ideal agent (high quality of bowel cleansing, safety, convenience, tolerability and affordability) (9,10). Polyethylene glycol (PEG) regimens are widely recommended as laxative agents for routine colonoscopy by most of the endoscopy societies (3,10). Those regimens provide a high quality of bowel preparation and are considered safe in most cases. However, small groups of patients have poor compliance and tolerability to PEG-based regimens due to its side effects and/or high volume necessary to complete the preparation (11,12).

Although mannitol solution is avoided in several countries due to anecdotal cases of colonic explosion, it is routinely used as a laxative agent in most of the healthcare centers in Brazil and in some centers in Venezuela and Colombia because of its low costs, high-quality bowel cleansing and low complication rates (13-16).

This study was aimed to assess tolerance and acceptability of the bowel preparation using either PEG or mannitol solution.

**MATERIALS AND METHODS**

**Study design**

This was a prospective, transversal, randomized study of patients underwent colonoscopies that received either PEG or mannitol solution as bowel preparation. This study followed the Declaration of Helsinki and was approved by the ethics committee of the Department of Medical Education and Research, Escuela de Ciencias de la Salud “Francisco Battistini Casalta”, Universidad de Oriente.

**Patients**

We enrolled prospectively 140 patients who met the selection criteria from the gastroenterology consultation of three healthcare centers in Venezuela: Centro Clínico Andrés Bello, Ciudad Bolívar (n=50); Hospital Militar “Dr. Carlos Arvelo”, Caracas (n=40) and Hospital de Clínicas Caracas, Caracas (n=50), between August and October, 2018. All patients were fully informed about the procedure and provided written informed consent.

Selection criteria included: Adult patients with indications of screening for CRC or with suspected large bowel diseases. Exclusion criteria were as follows: bowel obstruction, pregnant women, hemodynamic instability, hypersensitivity to PEG or mannitol solution, illiterate patients or unable to complete the questionnaires.

Patients were allocated to receive either PEG or mannitol solution by simple random sampling.

**Diet**

Patients received a dietary plan with a low-fiber diet, which had to be started in the morning of the day preceding colonoscopy.

**PEG preparation**

A PEG-electrolyte powder was used (Colayte®, Renova Industria Farmacéutica, Venezuela). Each package of Colayte® contains: PEG 3350 60 g, sodium chloride 1.460 g; potassium chloride 0.745 g; sodium bicarbonate 1.680 g and anhydrous sodium sulfate 5.680 g. Each package was diluted in one liter of water. Preparation was standardized as follows: the day before the examination, the patient received 2 l of PEG solution, beginning at 8 p.m. (1 glass of 250 ml every 10 minutes). On the day of colonoscopy, the patient drank other 2 l of PEG solution, beginning at 4 a.m.

**Mannitol preparation**

A 10% mannitol solution (Laboratorio Behrens, Venezuela) was used. Each 500-ml-bottle of mannitol was further diluted in 500 ml of water. The preparation was divided into two phases. On the day preceding colonoscopy, the patient was given one liter of mannitol (500 ml of mannitol + 500 ml of water), beginning at 8 p.m. (1 glass every 10 minutes). On the day of colonoscopy, the patient drank other 2 l of PEG solution, beginning at 4 a.m.

**Colonoscopic procedure**

The procedure was performed in a digestive endoscopy unit in the morning with conscious sedation. The colonoscope was introduced into the rectum and under direct visualization advanced to the cecum. Bowel preparation was scored by using the Boston Bowel Preparation Scale (BBPS) (17). During the withdrawal of the scope, the colonic mucosa was inspected, findings were recorded, biopsies were taken and therapeutic procedures were performed when necessary. After the procedure, the patients were taken to a recovery room.
Questionnaires

A questionnaire about the bowel preparation experience was given to the patients after they had left the recovery room. The questionnaire had three parts. The first part assessed the tolerance by nine 4-point-scale questions (1 = none, 2 = mild, 3 = moderate and 4 = severe). The items evaluated were nausea, abdominal pain, bloating, anal irritation, and overall experience during the preparation and post-procedure discomfort, disagreeable flavor, burden of the volume ingested and cost of the preparation. The second part was a question about the most unpleasant burden of the preparation. The last one evaluated the acceptability by asking the willingness to use the same bowel preparation in future colonoscopies.

Statistical analysis

Chi-square was applied for dichotomous categorical data. Mann–Whitney U-test was used for ordinal categorical data. A p value <0.05 was considered statistically significant. Statistical analyzes were calculated by using IBM® SPSS® Statistics 21.0.

RESULTS

One hundred forty patients were randomized in groups (PEG group: n=70; mannitol group: n=70). The mean age was 58.94 years with a standard deviation of 14.38 years. Screening for colorectal cancer (55.7%) was the most frequent indication for colonoscopy. Thirty percent of the patients had no pathological findings during the colonoscopy. Baseline patient and clinical characteristics are summarized in Table 1.

High quality of bowel preparation was achieved in both groups. The mean of the BBPS score was 8.06 ± 0.96 and 8.10 ± 0.96 in the mannitol group and in the PEG group, respectively (p=0.75). Cecal intubation was possible in all cases.

Table 1. Baseline and clinical characteristics.

| Variable                          | Mannitol group n=70 | PEG group n=70 | p value |
|-----------------------------------|---------------------|----------------|---------|
| Age (years), mean (±SD)           | 58.94 (±14.38)      |                |         |
| Sex, n (%)                        |                     |                |         |
| Male                              | 63 (45)             |                |         |
| Female                            | 77 (55)             |                |         |
| Indication of colonoscopy, n (%)  |                     |                |         |
| Screening for CRC*                | 78 (55.7)           |                |         |
| Lower gastrointestinal bleeding   | 21 (15.0)           |                |         |
| Chronic abdominal pain            | 12 (8.6)            |                |         |
| Anemia                            | 11 (7.9)            |                |         |
| Constipation                      | 8 (5.7)             |                |         |
| Chronic diarrhea                  | 5 (3.6)             |                |         |
| Weight loss                       | 4 (2.9)             |                |         |
| Proctalgia                        | 1 (0.7)             |                |         |
| Diagnosis, n (%)                  |                     |                |         |
| No positive findings              | 43 (30.7)           |                |         |
| Colonic diverticula               | 40 (28.6)           |                |         |
| Adenoma with LGD†                 | 20 (14.3)           |                |         |
| ADC†                              | 11 (7.9)            |                |         |
| UC‡                              | 10 (7.1)            |                |         |
| Adenoma with HGDI§                | 6 (4.3)             |                |         |
| Angiectasia                       | 4 (2.9)             |                |         |
| Lipoma                            | 3 (2.1)             |                |         |
| Ischemic colitis                  | 2 (1.4)             |                |         |
| Crohn’s disease                   | 1 (0.7)             |                |         |

*Colorectal cancer; †Low-grade dysplasia; ‡Adenocarcinoma; §Ulcerative colitis; ††High-grade dysplasia.

Table 2. Differences of tolerability of the bowel preparation according to a 4-point scale* questions.

| Variable                          | Mannitol group n=70 | PEG group n=70 | p value |
|-----------------------------------|---------------------|----------------|---------|
| Nausea                            | 2.01 (1.04)         | 2.74 (0.94)    | <0.001  |
| Abdominal pain                    | 1.36 (0.61)         | 1.33 (0.53)    | 0.990   |
| Bloating                          | 2.01 (1.32)         | 2.10 (0.95)    | 0.254   |
| Anal irritation                    | 1.24 (0.43)         | 1.31 (0.46)    | 0.348   |
| Overall experience                | 1.56 (0.75)         | 1.86 (0.74)    | 0.012   |
| Post-procedure discomfort          | 1.34 (0.61)         | 1.77 (0.72)    | <0.001  |
| Disagreeable flavor               | 1.41 (0.84)         | 2.91 (0.91)    | <0.001  |
| Excessive volume perception        | 2.26 (0.89)         | 3.16 (0.73)    | <0.001  |
| Burden of costs                   | 2.10 (0.66)         | 3.19 (0.70)    | <0.001  |

*Four-point scale: 1=None; 2=mild; 3=moderate; 4=severe

Figure 1 shows the differences of burden according to the answers from the questionnaires between the mannitol group and the PEG group. Patients perceived more burdensome the bowel preparation with PEG than mannitol solution for the variables nausea, overall experience, post-procedure discomfort, disagreeable flavor, volume ingested and cost (p<0.05). A similar tolerance was reported for abdominal pain, bloating and anal irritation (p>0.05) (Table 2).

The most unpleasant burden in the mannitol group was nausea (27.1%), followed by volume ingested...
Mannitol solution and polyethylene glycol as bowel preparation for colonoscopy

Piñerúa-Gonsálvez JF, et al

Rev Gastroenterol Peru. 2020;40(1):7-12

(14.2%), whereas in the PEG group, nausea (25.7%) and disagreeable flavor (24.2%) were the worst burdens. It should be noted that in the mannitol group, 24.3% of the patients reported none major burden (Figure 2). The same type of bowel preparation would be used again in future colonoscopies in the 82.9% of the patients from the mannitol group versus 71.4% of the patients from the PEG group ($p=0.10$).

DISCUSSION

A High-quality bowel preparation is a key element for the success of colonoscopy because is related to higher adenoma detection rate and lower healthcare costs and complication rates during the procedure. Therefore, the factors that influence on the bowel preparation can also impact the yield of colonoscopy. Bowel preparation remains one of the main impediments to undergo colonoscopy since it is usually perceived as an unpleasant experience by most patients. Moreover, greater technical difficulty and lower accuracy of colonoscopy have been associated with a patient-perceived negative experience of bowel preparation.

PEG is an isotonic agent, which passes through the bowel with neither absorption nor secretion. The use

Figure 1. Tolerability of evaluated burdens on a 4-point scale.

Figure 2. Profile of the most unpleasant burden during bowel preparation.
of PEG-electrolyte solutions is considered the standard regimen of bowel preparation (10). This formulation achieves high quality of bowel cleansing compared with other agents. However, many patients report low tolerance due to its disagreeable flavor and burden associated with the larger volumes intake, routinely 2–4 l (20,21). Moreover, in some developing countries, PEG-based regimens are expensive and unavailable (22).

Mannitol is an osmotic diuretic agent, which is insignificantly absorbed by the gastrointestinal tract when administered orally, leading to an osmotic diarrhea (23,24). This formulation has been used as bowel preparation for colorectal surgery and colonoscopy in several countries because of its low cost, easy administration, pleasant flavor, good tolerability and high quality of bowel cleansing (16,22,25,26). Despite this fact, this formulation has been avoided in the United States and Europe due to a few cases of colonic explosion during therapeutic colonoscopy (27–31). To trigger a colonic explosion, the presence of combustible gases like hydrogen and methane, presence of oxygen (concentration above 5%) and application of a heat source are necessary. As a non-absorbable carbohydrate, mannitol is fermented by bacteria in the colonic lumen, which produces hydrogen and methane. Concentration of hydrogen and methane must be above 4% and 5%, respectively to be considered potentially explosive (32). Nonetheless, in a study by Paulo et al. (9), in which the methane concentration was measured both during colonoscopy and after gas exchange (air insufflation and aspiration) in patients who had received either mannitol or sodium phosphate, none of the patients in the mannitol group had detectable levels of methane after gas exchange. Therefore, those results showed the mannitol use was as safe as sodium phosphate considering methane measurements.

In the current study, the difference in the cleansing quality was not statistically significant between the mannitol group and the PEG group, achieving BBPS scores ≥6. This fact has been reported in several trials, which have shown high levels of cleanliness of the colon in both types of formulations (14–16). In a study by Vieira et al. (14), patients who received mannitol achieved a mean BBPS score 8.50 versus 8.54 in the group that took the PEG regimen, which is similar to the findings in our study (mannitol group: 8.06 versus PEG group: 8.10).

There were differences of tolerability between both sorts of cleansing agents in the present study. In the mannitol group, nausea, overall experience, post-procedure discomfort, disagreeable flavor and volume ingested were less burdensome than in the PEG group. On the other hand, abdominal pain, bloating and anal irritation were well tolerated in both groups without significant differences. We included in the questionnaire the item burden of the preparation cost, which has been not included in previous researches. The cost of the preparation was more burdensome in the PEG group than in the mannitol group. Our results contrast with those obtained in the study by Vieira et al. (14) in which the patients reported more burden in the mannitol group than in the PEG group. This fact could be explained by the additional dilution of 500 ml of 10% mannitol in 500 ml of water that we performed, as well as, it was given a split-dose of mannitol solution (1 l of the preparation the night before and then 1 l the at the same day of the colonoscopy) instead of a single-dose at the same day of the colonoscopy.

In both groups nausea was the main burden of the bowel preparation, which is consistent with the results of previous researches (15,16). Even though split-dose bowel preparation was used in both groups, patients still perceived nausea as a major complaint. Nevertheless, nausea was less burdensome in the mannitol group. None of the patients were unable to complete the preparation because of this burden. We usually advise patients with nausea to space the intake of the preparation every 30 minutes, which manages to mitigate this complaint in most cases.

No significant differences were found with regard to acceptance between the Mannitol and PEG groups. Both groups showed high levels of acceptability (mannitol group: 82.9% versus PEG group 71.4%, p = 0.10). However, the mannitol solution was perceived more tolerable.

This study has some limitations that should be discussed. First of all, it was not a blinded study, which could have led to observer bias. Secondly, the sample size was relatively small because most of the patients who attend to the gastroenterology consultation in our country cannot afford the costs related to colonoscopy, which makes it difficult to generalize our findings. Due to those limitations, we suggest carrying out multicenter, double-blind studies with larger sample size in order to corroborate the results of the present study.

In summary, acceptance of the bowel preparation between mannitol solution and PEG was comparable. Nevertheless, mannitol solution was better tolerated by patients in regard to overall experience, nausea, post-procedure discomfort, disagreeable flavor, volume ingested and cost. Thus, mannitol solution seems to be a safe alternative to bowel cleansing before colonoscopy.

Acknowledgements
This study received the collaboration from Edgar José Villanueva Jiménez for English edition.

Disclosure of funding: no funding received.

Declared conflict of interest of all authors: none.
REFERENCES

1. Force USPST, Bibbins-Domingo K, Grossman DC, Curry SJ, Davidson KW, Epling JW, Jr., et al. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. Jama. 2016;315(23):2564-73.

2. Ngu WS, Rees C. Can technology increase adenoma detection rate? Therapeutic advances in gastroenterology. 2018;11:1756283X17746311.

3. Hassan C, East J, Radaei F, Spada C, Benamouzig R, Bisschops R, et al. Bowel preparation for colonoscopy: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - Update 2019. Endoscopy. 2019;51(8):775-94.

4. Guo R, Wang Yj, Liu M, Ge J, Zhang JY, Ma L, et al. The effect of quality of segmental bowel preparation on adenoma detection rate. BMC Gastroenterol. 2019;19(1):119.

5. Clark BT, Rustagi T, Laine L. What level of bowel prep quality requires early repeat colonoscopy: systematic review and meta-analysis of the impact of preparation quality on adenoma detection rate. Am J Gastroenterol. 2014;109(11):1714-23; quiz 24.

6. Rex DK, Imperiale TF, Latiniovich DR, Bratcher LL. Impact of bowel preparation on efficiency and cost of colonoscopy. Am J Gastroenterol. 2002;97(7):1696-700.

7. Yadlapati R, Johnston ER, Gregory JD, Ciolino JD, Cooper A, Keswani RN. Predictors of Inadequate Inpatient Colonoscopy Preparation and Its Association with Hospital Length of Stay and Costs. Dig Dis Sci. 2015;60(11):3482-90.

8. Jones RM, Devers KJ, Kuzel AJ, Woolf SH. Patient-reported barriers to colorectal cancer screening: a mixed-methods analysis. Am J Prev Med. 2010;38(5):508-16.

9. Paulo GA, Martins FP, Macedo EP, Goncalves ME, Ferrari AP. Safety of mannitol use in bowel preparation: a prospective assessment of intestinal methane (CH4) levels during colonoscopy after mannitol and sodium phosphate (NaP) bowel cleansing. Arq Gastroenterol. 2016;53(3):196-202.

10. Committee ASoP, Saltzman JR, Cash BD, Pasha SF, Early DS, Committee ASoP; Davidson KW, Epling JW, Jr., et al. Bowel preparation before colonoscopy. Gastrointest Endosc. 2015;81(4):781-94.

11. Buliga IM, Paun AC, Bodeanu R, et al. Comparison of colon-cleansing methods. J Med Life. 2012;5(4):477-82.

12. Marshall JB, Pineda JJ, Barthel JS, King PD. Prospective, randomized trial comparing sodium phosphate solution with polyethylene glycol-electrolyte lavage for colonoscopy preparation. Gastrointest Endosc. 1993;39(5):631-4.

13. Sousa JB, Silva SM, Fernandes MB, Nobrega AC, Almeida RM, Oliveira PG. Colonoscopies performed by resident physicians in a university teaching hospital: a consecutive analysis of 1000 cases. ABCD, Arq Bras Cir Dig. 2012;25(1):9-12.

14. Vieira MC, Hashimoto CL, Carrilho FJ. Bowel preparation for performing a colonoscopy: prospective randomized comparison study between a low-volume solution of polyethylene glycol and bisacodyl versus bisacodyl and a mannitol solution. Arq Gastroenterol. 2012;49(2):162-8.

15. Avila A, Parada JL, Bozit S. Preparación intestinal colónica con polietilenoglicol y manitol: efectividad según la escala de Boston. Gen. 2013;67:76-81.

16. Chacaltana Mendoza A, Rodriguez Ulla C. [Comparative study between mannitol 10% and polyethylene glycol (corrected) in colorectal polypectomy in inpatients of FAP Central Hospital]. Rev Gastroenterol Peru. 2008;28(2):125-22.

17. Lai EL, Calderwood AH, Doreys G, Fix OK, Jacobson BC. The Boston bowel preparation scale: a valid and reliable instrument for colonoscopy-oriented research. Gastrointest Endosc. 2009;69(3 Pt 2):620-5.

18. Alvarez-Gonzalez MA, Pantaleon MA, Flores-Le Roux JA, Zaffalon D, Amoros J, Bessa X, et al. Randomized Clinical Trial: A Normocaloric Low-Fiber Diet the Day Before Colonoscopy Is the Most Effective Approach to Bowel Preparation in Colorectal Cancer Screening Colonoscopy. Dis Colon Rectum. 2019;62(4):491-7.

19. Holt EW, Yimam KK, Ma H, Shaw RE, Sundberg RA, Verhille MS. Patient tolerability of bowel preparation is associated with polyp detection rate during colonoscopy. J Gastrointestin Liver Dis. 2014;23(2):135-40.

20. Harrison NM, Hjelkrem MC. Bowel cleansing before colonoscopy: Balancing efficacy, safety, cost and patient tolerance. World J Gastroenterol. 2016;8(1):4-12.

21. Park HS, Han SC, Kwon HY, et al. Commonly used preparations for colonoscopy: efficacy, tolerability, and safety—a Canadian Association of Gastroenterology position paper. Can J Gastroenterol. 2006;20(11):699-710.

22. Askarpour S, Peyvasteh M, Dastyar AA, Javarizadeh E. Bowel preparation for colorectal surgery: with and without mannitol. Prz Gastroenterol. 2013;8(5):305-7.

23. Muller S, Francesconi CF, Maguilnik I, Breyer HP. Randomized clinical trial comparing sodium picosulfate with mannitol on the preparation FOR colonoscopy in hospitalized patients. Arq Gastroenterol. 2007;44(3):244-9.

24. Bertram Katzung AT. Diuretic Agents. Basic & Clinical Pharmacology. 13th ed. New York: Mc Graw Hill LANGE; 2014. p. 249-69.

25. de Moura DT, Guedes H, Tortoreto V, Arauaje TP, de Moura EG, Roman JP, et al. [Comparison of colon-cleansing methods in preparation for colonoscopy-comparative of solutions of mannitol and sodium picosulfate]. Rev Gastroenterol Peru. 2016;36(4):293-7.

26. Kaisers-Junior RL, LG DE-Q, Flamini-Junior M, Faria MAG, Campo JCO, VL DE-O, et al. New Bowel Preparation Technique for Colonoscopy: Clinical Trial Comparing Aquate, Mannitol and Arq Bras Cir Dig. 2018;31(3):e1393.

27. Bisson B. Methane gas explosion during colonoscopy. Gastroenterol Nurs. 1997;20(4):136-7.

28. Raillat A, de Saint-Julien J, Abgrall J. [Comparison of colon-cleansing methods]. Arq Gastroenterol. 2003;39(3):640-4.

29. Bond JH, Levy M, Levitt MD. Explosion of hydrogen gas in the colon during proctosigmoidoscopy. Gastrointest Endosc. 1976;23(1):41-2.

30. Bigard MA, Gaucher P, Lasalle C. Fatal colonic explosion during colonoscopy: with polyp detection rate during colonoscopy. J Gastrointestin Liver Dis. 2009;18(6):301-2.

31. Bond JH, Levy M, Levitt MD. Explosion of hydrogen gas in the colon during proctosigmoidoscopy. Gastrointest Endosc. 1979;77(6):1307-10.

32. Shinagawa N, Mizuno H, Shibata Y, Ura J, Katsumi K, Ito M, et al. Gas explosion during diathermy colotomy. Br J Surg. 1985;72(4):306.

33. Ladas SD, Karamanolis G, Ben-Soussan E. Colonic gas explosion during therapeutic colonoscopy with electrocautery. World J Gastroenterol. 2007;13(40):5295-8.

Correspondence:
Jean Felix Piñerúa-Gonsález
Centro Clínico Andrés Bello, Ciudad Bolívar, Venezuela.
Phone: +584142718016.
E-mail: jeanfelixmedicina@hotmail.com